Tags

Type your tag names separated by a space and hit enter

Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
Neurodegener Dis Manag. 2020 Jul 03 [Online ahead of print]ND

Abstract

Schizophrenia is a disabling psychiatric disorder marked by progressive loss of functionality in activities of daily living with each relapse. Antipsychotics, the mainstay of therapy for schizophrenia, treat hallucinations and delusions but may have intolerable side effects, including metabolic disturbances and extrapyramidal symptoms. Brexpiprazole, a second-generation antipsychotic with dopamine partial agonist properties, was approved by the US FDA in 2015 for the treatment of schizophrenia and adjunctive treatment of major depressive disorder and by the EU in 2018 for adults with schizophrenia. Additionally, brexpiprazole has recently been studied for the treatment of agitation in Alzheimer's dementia, an area of largely unmet need. Overall, well-tolerated brexpiprazole expands the armamentarium of treatment options available for these conditions.

Authors+Show Affiliations

Department of Pharmacy, McLean Hospital, 115 Mill Street Belmont, MA 02478, USA.Department of Pharmacy, Hackensack University Medical Center, 30 Prospect Ave, Hackensack, NJ 07601, USA.Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, Department of Pharmacy, Monmouth Medical Center, 300 Second Avenue, Long Branch, NJ 07740, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32618483

Citation

Stummer, Lauren, et al. "Brexpiprazole in the Treatment of Schizophrenia and Agitation in Alzheimer's Disease." Neurodegenerative Disease Management, 2020.
Stummer L, Markovic M, Maroney M. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease. Neurodegener Dis Manag. 2020.
Stummer, L., Markovic, M., & Maroney, M. (2020). Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2020-0013
Stummer L, Markovic M, Maroney M. Brexpiprazole in the Treatment of Schizophrenia and Agitation in Alzheimer's Disease. Neurodegener Dis Manag. 2020 Jul 3; PubMed PMID: 32618483.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease. AU - Stummer,Lauren, AU - Markovic,Marija, AU - Maroney,Megan, Y1 - 2020/07/03/ PY - 2020/7/4/entrez KW - Alzheimer’s disease KW - D2 partial agonist KW - Rexulti® KW - agitation KW - brexpiprazole KW - dementia KW - schizophrenia KW - second-generation antipsychotic JF - Neurodegenerative disease management JO - Neurodegener Dis Manag N2 - Schizophrenia is a disabling psychiatric disorder marked by progressive loss of functionality in activities of daily living with each relapse. Antipsychotics, the mainstay of therapy for schizophrenia, treat hallucinations and delusions but may have intolerable side effects, including metabolic disturbances and extrapyramidal symptoms. Brexpiprazole, a second-generation antipsychotic with dopamine partial agonist properties, was approved by the US FDA in 2015 for the treatment of schizophrenia and adjunctive treatment of major depressive disorder and by the EU in 2018 for adults with schizophrenia. Additionally, brexpiprazole has recently been studied for the treatment of agitation in Alzheimer's dementia, an area of largely unmet need. Overall, well-tolerated brexpiprazole expands the armamentarium of treatment options available for these conditions. SN - 1758-2032 UR - https://www.unboundmedicine.com/medline/citation/32618483/Brexpiprazole_in_the_treatment_of_schizophrenia_and_agitation_in_Alzheimer's_disease L2 - https://www.futuremedicine.com/doi/10.2217/nmt-2020-0013?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.